VAS101, a Novel Curcumin Transdermal Formulation, Reverses Some Clinical Hallmarks of Aging
Hand-out
Press Releases
March 17, 2025

VAS101, a Novel Curcumin Transdermal Formulation, Reverses Some Clinical Hallmarks of Aging

SUMMIT, N.J., March 17, 2025 /PRNewswire/ -- In a new study published in the journal GeroScience, VAS101 (Vasceptor®), a novel curcumin transdermal formulation developed by Vascarta Inc. (Summit, NJ, USA),

bradford

The Bradford Era

More by this Author
Local & Social